About Us
Our Story
Leadership
Board of Directors
Our Science
Overview
Platform and Programs
Manufacturing
Our Pipeline
Investors & Media
Company Overview
Press Releases
Events and Presentations
Publications
FAQs
Careers
Contact Us
Publications
Presentations
Filter By Year:
2021
2022
February 9, 2022
CytoImmune Therapeutics to Participate in the 2022 BIO CEO & Investor Conference and the SVB Leerink Global Healthcare Conference
July 10, 2021
Abstract LB154: A potent human CAR NK cell therapy directed against pancreatic cancer
Load more
Publications
Filter By Year:
2010
2013
2014
2015
2017
2021
2023
March 23, 2023
Puerto Rico Tries to Woo Big Business Amid Widespread Challenges
February 1, 2021
CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma
January 1, 2021
CAR-NK cell immunotherapy: Development and challenges toward an off-the-shelf product
November 4, 2017
The Broad Spectrum of Human Natural Killer Cell Diversity
July 1, 2015
CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells
April 1, 2014
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
December 1, 2013
Location and cellular stages of natural killer cell development
September 1, 2010
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody
Load more
Press Releases
Events and Presentations
